Development
SpringWorks Therapeutics, Inc.
SWTX
$46.99
$0.010.02%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 5.45M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.45M | -- | -- | -- | -- |
| Cost of Revenue | 422.00K | -- | -- | -- | -- |
| Gross Profit | 5.03M | -- | -- | -- | -- |
| SG&A Expenses | 59.84M | 46.55M | 46.99M | 44.18M | 40.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.91M | 84.00M | 82.85M | 77.70M | 78.45M |
| Operating Income | -98.46M | -84.00M | -82.85M | -77.70M | -78.45M |
| Income Before Tax | -94.32M | -79.44M | -77.93M | -73.42M | -74.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.32M | -79.44M | -77.93M | -73.42M | -74.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.32M | -79.44M | -77.93M | -73.42M | -74.18M |
| EBIT | -98.46M | -84.00M | -82.85M | -77.70M | -78.45M |
| EBITDA | -97.93M | -83.51M | -82.47M | -77.45M | -78.20M |
| EPS Basic | -1.44 | -1.27 | -1.25 | -1.18 | -1.19 |
| Normalized Basic EPS | -0.90 | -0.79 | -0.78 | -0.74 | -0.74 |
| EPS Diluted | -1.44 | -1.27 | -1.25 | -1.18 | -1.19 |
| Normalized Diluted EPS | -0.90 | -0.79 | -0.78 | -0.74 | -0.74 |
| Average Basic Shares Outstanding | 65.34M | 62.52M | 62.46M | 62.33M | 62.27M |
| Average Diluted Shares Outstanding | 65.34M | 62.52M | 62.46M | 62.33M | 62.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |